We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Txa6.0
Tranexamic Acid (topical) Research
Mostly mechanism / observationalHigh safety
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Tranexamic Acid (topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 44 participants.
Based on 6 studies · 2 meta-analyses · 3 RCTs · 114 total participants
Confidence
High
By outcome
Skin tone & pigmentationReduction in melasma/stubborn pigmentation, comparable to hydroquinone in small trials (cosmetic, not a health outcome) · 8-12 weeks
Mostly mechanism / observational6 studies
Safety profile
Too few graded studies2 studies
Active research area
4 studies in the last 5 years · Latest meta-analysis: 2024
201420202026
1Meta-Analysis2021
The ranking of relative efficacy compared with placebo in descending order was Q-switched Nd:Yag 1,064-nm laser, intense pulsed light, ablative fractional laser, triple combined cream, topical vitamin C, oral tranexamic acid, peeling, azelaic acid, microneedles, topical tranexamic acid.
Liu Y, Wu S, Wu H, Liang X, Guo D, Zhuo F. · Front Med (Lausanne) (2021)
Network meta-analysis of 59 RCTs ranking 14 melasma therapies
Oral TXA ranked above topical TXA, and lasers, triple-combination cream, and topical vitamin C all outranked topical TXA
Topical TXA carried a higher side-effect rate (36.75%) than oral TXA (17.6%) — the key counter-evidence that topical is not a top performer
A significant decreasing trend was observed in the MASI score of both groups with no significant difference between them during the study (P < 0.05).
Ebrahimi B, Naeini FF. · J Res Med Sci (2014)
Double-blind 12-week split-face RCT in 50 women: 3% topical TXA on one side vs 3% hydroquinone + 0.01% dexamethasone on the other, twice daily
Both sides showed significant MASI reductions with no significant difference between topical TXA and the hydroquinone combination
Side effects were significantly more prominent with hydroquinone + dexamethasone than with TXA (P = 0.01)
5RCTn=20 · very small study2024
There were no statistically significant differences in PtGA scores between the 3% TA group and the 4% HQ group.
Yasnova N, Sirait SP, Rahmayunita G. · Acta Dermatovenerol Alp Pannonica Adriat (2024)
Double-blind 8-week split-face RCT in 20 skin-of-color subjects comparing 3% topical TXA cream vs 4% hydroquinone cream
Both produced significant mMASI declines at weeks 4 and 8 with no significant difference in patient global assessment
Concludes topical 3% TXA is as effective and safe as 4% HQ — but the trial is small (n=20)
6In Vitro2026
TXA directly inhibited melanin synthesis in B16 melanoma cells, with an additive effect when combined with α-arbutin. In keratinocytes and macrophages, TXA attenuated inflammatory responses triggered by the plasminogen/plasmin (Plg/Plm) pathway.
Hushcha Y, Giuliani AL, Fernanda M, Bononi I, Mazziotta C, Rotondo JC, De Mattei M. · Cell Biol Int (2026)
In-vitro mechanism study: TXA directly inhibited melanin synthesis in B16 melanoma cells, additive with alpha-arbutin
TXA attenuated plasminogen/plasmin-pathway-driven inflammatory responses in keratinocytes and macrophages
Supports the proposed plasmin-inhibition mechanism, though evidence is cell-line, not human skin